NASDAQ: DAWN

Day One Biopharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 4 Wall Street analysts covering (NASDAQ: DAWN) stock is to Strong Buy DAWN stock.

Out of 4 analysts, 2 (50%) are recommending DAWN as a Strong Buy, 2 (50%) are recommending DAWN as a Buy, 0 (0%) are recommending DAWN as a Hold, 0 (0%) are recommending DAWN as a Sell, and 0 (0%) are recommending DAWN as a Strong Sell.

If you're new to stock investing, here's how to buy Day One Biopharmaceuticals stock.

(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Day One Biopharmaceuticals's revenue in 2024 is $0.On average, 6 Wall Street analysts forecast DAWN's revenue for 2024 to be $1,129,536,649, with the lowest DAWN revenue forecast at $297,108,510, and the highest DAWN revenue forecast at $1,863,918,978. On average, 6 Wall Street analysts forecast DAWN's revenue for 2025 to be $7,146,246,139, with the lowest DAWN revenue forecast at $1,319,511,326, and the highest DAWN revenue forecast at $11,766,021,321.

In 2026, DAWN is forecast to generate $19,412,982,685 in revenue, with the lowest revenue forecast at $12,755,567,430 and the highest revenue forecast at $25,530,971,223.

According to 4 Wall Street analysts that have issued a 1 year DAWN price target, the average DAWN price target is $38.25, with the highest DAWN stock price forecast at $44.00 and the lowest DAWN stock price forecast at $34.00.

On average, Wall Street analysts predict that Day One Biopharmaceuticals's share price could reach $38.25 by Mar 26, 2025. The average Day One Biopharmaceuticals stock price prediction forecasts a potential upside of 142.86% from the current DAWN share price of $15.75.

(NASDAQ: DAWN) forecast ROE is N/A, which is considered weak.